Home > In process > Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment. > print

001     284029
005     20260119110849.0
024 7 _ |a 10.1016/j.ebiom.2025.106090
|2 doi
024 7 _ |a pmid:41443080
|2 pmid
024 7 _ |a pmc:PMC12800623
|2 pmc
037 _ _ |a DZNE-2026-00072
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Baumeister, Hannah
|0 P:(DE-2719)9001499
|b 0
|e First author
|u dzne
245 _ _ |a Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768810354_6722
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Spinocerebellar ataxia type 3 (SCA3) is characterised by progressive brain atrophy, with regional volume loss detectable via MRI prior to clinical manifestation. We aimed to identify the previously unknown sequence of brain atrophy in SCA3 and evaluate whether this sequence can be translated into an atrophy staging framework to enable accurate clinical prognosis and trial enrichment.We included data from 322 SCA3 mutation carriers, enrolled in observational studies conducted across Europe, the Americas, and Asia. Participants underwent follow-up assessments up to five years after baseline. The Subtype and Stage Inference machine learning algorithm was applied to estimate the most likely atrophy sequence(s) from baseline anatomical MRI. The Scale for the Assessment and Rating of Ataxia (SARA) was used to capture ataxia severity. Atrophy stages were analysed in relation to SARA and time from disease onset. Interventional trials were simulated to estimate required sample sizes under different atrophy stage eligibility criteria.We identified a uniform sequence of brain atrophy in SCA3, characterised by earliest volumetric decline in the caudal brainstem and substantial involvement of the white matter. Atrophy stage was associated with both SARA and time from disease onset. Atrophy staging outperformed single-region volumetrics in predicting SARA over time. Applying atrophy stage cut-offs substantially reduced the sample sizes needed to adequately power hypothetical clinical trials.These findings yield mechanistic insights into the progression of neurodegeneration in SCA3 and possess immediate translational relevance, facilitating patient stratification and sample enrichment for interventional trials.National Ataxia Foundation (NAF).
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Ataxia
|2 Other
650 _ 7 |a Disease progression modelling
|2 Other
650 _ 7 |a Imaging biomarker
|2 Other
650 _ 7 |a Machine learning
|2 Other
650 _ 7 |a Movement disorders
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Atrophy
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: pathology
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: diagnosis
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: genetics
|2 MeSH
650 _ 2 |a Machado-Joseph Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
693 _ _ |0 EXP:(DE-2719)DANCER-20150101
|5 EXP:(DE-2719)DANCER-20150101
|e Degeneration Controls and Relatives
|x 1
693 _ _ |0 EXP:(DE-2719)ESMI-20140101
|5 EXP:(DE-2719)ESMI-20140101
|e European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative
|x 2
700 1 _ |a Wegner, Philipp
|0 P:(DE-2719)9002349
|b 1
|u dzne
700 1 _ |a Ferreira, Mónica
|0 P:(DE-2719)9003289
|b 2
|u dzne
700 1 _ |a Schaprian, Tamara
|0 P:(DE-2719)2812594
|b 3
|u dzne
700 1 _ |a França, Marcondes C
|b 4
700 1 _ |a Rezende, Thiago Junqueira Ribeiro
|b 5
700 1 _ |a Muro Martinez, Alberto Rolim
|b 6
700 1 _ |a Jiang, Hong
|b 7
700 1 _ |a Chen, Zhao
|b 8
700 1 _ |a Weihua, Liao
|b 9
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 10
|u dzne
700 1 _ |a Koyak, Berkan
|0 P:(DE-2719)9001550
|b 11
|u dzne
700 1 _ |a Önder, Demet
|0 P:(DE-2719)9000685
|b 12
|u dzne
700 1 _ |a van de Warrenburg, Bart
|b 13
700 1 _ |a van Gaalen, Judith
|b 14
700 1 _ |a Durr, Alexandra
|b 15
700 1 _ |a Coarelli, Giulia
|b 16
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 17
|u dzne
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 18
|u dzne
700 1 _ |a Giunti, Paola
|b 19
700 1 _ |a Garcia-Moreno, Hector
|b 20
700 1 _ |a Öz, Gülin
|b 21
700 1 _ |a Joers, James
|b 22
700 1 _ |a Timmann, Dagmar
|b 23
700 1 _ |a Thieme, Andreas G
|b 24
700 1 _ |a Jacobi, Heike
|0 P:(DE-2719)2811564
|b 25
700 1 _ |a de Vries, Jeroen
|b 26
700 1 _ |a Barker, Peter
|b 27
700 1 _ |a Onyike, Chiadikaobi
|b 28
700 1 _ |a Ratai, Eva-Maria
|b 29
700 1 _ |a Schmahmann, Jeremy D
|b 30
700 1 _ |a Reetz, Kathrin
|b 31
700 1 _ |a Infante, Jon
|b 32
700 1 _ |a Huebener-Schmid, Jeannette
|b 33
700 1 _ |a Kuegler, David
|0 P:(DE-2719)2814290
|b 34
|u dzne
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 35
|u dzne
700 1 _ |a Berron, David
|0 P:(DE-2719)2812972
|b 36
|u dzne
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 37
|e Last author
|u dzne
700 1 _ |a DELCODE/DANCER
|b 38
|e Collaboration Author
700 1 _ |a Groups, ESMI MRI Study
|b 39
|e Collaboration Author
700 1 _ |a Lüsebrink-Rindsland, Jann Falk Silvester
|0 P:(DE-2719)9002520
|b 40
|e Contributor
|u dzne
700 1 _ |a HetzerBernsen, StefanSarah
|b 41
|e Contributor
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 42
|e Contributor
700 1 _ |a Hellmann-Regen, Julian David Nicolai
|0 P:(DE-2719)9003016
|b 43
|e Contributor
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 44
|e Contributor
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 45
|e Contributor
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 46
|e Contributor
|u dzne
700 1 _ |a Kronmüller, Marie Theres
|0 P:(DE-2719)9003427
|b 47
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 48
|e Contributor
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 49
|e Contributor
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 50
|e Contributor
|u dzne
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 51
|e Contributor
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 52
|e Contributor
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 53
|e Contributor
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 54
|e Contributor
|u dzne
700 1 _ |a Gamez, Anna
|0 P:(DE-2719)9001536
|b 55
|e Contributor
|u dzne
700 1 _ |a Asperger, Hannah
|0 P:(DE-2719)9003181
|b 56
|e Contributor
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 57
|e Contributor
|u dzne
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 58
|e Contributor
|u dzne
700 1 _ |a Pracht, Eberhard
|0 P:(DE-2719)2810559
|b 59
|e Contributor
|u dzne
700 1 _ |a Stöcker, Tony
|0 P:(DE-2719)2810538
|b 60
|e Contributor
|u dzne
773 _ _ |a 10.1016/j.ebiom.2025.106090
|g Vol. 123, p. 106090 -
|0 PERI:(DE-600)2799017-5
|p 106090
|t EBioMedicine
|v 123
|y 2026
|x 2352-3964
856 4 _ |u https://pub.dzne.de/record/284029/files/DZNE-2026-00072.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/284029/files/DZNE-2026-00072.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001499
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002349
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9003289
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812594
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001510
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001550
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9000685
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811275
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2814290
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 35
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2812972
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)2811327
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 40
|6 P:(DE-2719)9002520
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 42
|6 P:(DE-2719)9000543
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 43
|6 P:(DE-2719)9003016
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 44
|6 P:(DE-2719)2812446
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 45
|6 P:(DE-2719)9002557
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 46
|6 P:(DE-2719)2810394
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 47
|6 P:(DE-2719)9003427
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 48
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 49
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 50
|6 P:(DE-2719)2811122
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 51
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 52
|6 P:(DE-2719)2000026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 53
|6 P:(DE-2719)2000032
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 54
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 55
|6 P:(DE-2719)9001536
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 56
|6 P:(DE-2719)9003181
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 57
|6 P:(DE-2719)9002382
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 58
|6 P:(DE-2719)2810273
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 59
|6 P:(DE-2719)2810559
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 60
|6 P:(DE-2719)2810538
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EBIOMEDICINE : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T08:51:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T08:51:17Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T08:51:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EBIOMEDICINE : 2022
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)5000070
|k AG Berron
|l Clinical Cognitive Neuroscience
|x 1
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 2
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 3
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 4
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 5
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 6
920 1 _ |0 I:(DE-2719)1040310
|k AG Reuter
|l Artificial Intelligence in Medicine
|x 7
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 8
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000070
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a I:(DE-2719)1040310
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21